Trade Verve Therapeutics, Inc. - VERV CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5.74 |
| Open | 5.65 |
| 1-Year Change | -14.13% |
| Day's Range | 5.65 - 5.87 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2025 | 5.73 | 0.08 | 1.42% | 5.65 | 5.89 | 5.61 |
| Apr 24, 2025 | 5.74 | 0.28 | 5.13% | 5.46 | 5.91 | 5.36 |
| Apr 23, 2025 | 5.43 | -0.07 | -1.27% | 5.50 | 5.93 | 5.43 |
| Apr 22, 2025 | 5.22 | 0.47 | 9.89% | 4.75 | 5.28 | 4.74 |
| Apr 21, 2025 | 4.75 | 0.30 | 6.74% | 4.45 | 5.47 | 4.40 |
| Apr 17, 2025 | 4.56 | 0.02 | 0.44% | 4.54 | 4.81 | 4.39 |
| Apr 16, 2025 | 4.48 | -0.38 | -7.82% | 4.86 | 4.91 | 4.25 |
| Apr 15, 2025 | 4.94 | 0.07 | 1.44% | 4.87 | 5.78 | 4.87 |
| Apr 14, 2025 | 4.09 | -0.05 | -1.21% | 4.14 | 4.28 | 3.53 |
| Apr 11, 2025 | 3.23 | -0.05 | -1.52% | 3.28 | 3.28 | 3.02 |
| Apr 10, 2025 | 3.04 | -0.25 | -7.60% | 3.29 | 3.29 | 2.92 |
| Apr 9, 2025 | 3.36 | 0.48 | 16.67% | 2.88 | 3.50 | 2.84 |
| Apr 8, 2025 | 2.95 | -0.54 | -15.47% | 3.49 | 3.53 | 2.89 |
| Apr 7, 2025 | 3.31 | -0.08 | -2.36% | 3.39 | 3.59 | 3.07 |
| Apr 4, 2025 | 3.60 | -0.09 | -2.44% | 3.69 | 3.69 | 3.44 |
| Apr 3, 2025 | 3.82 | 0.06 | 1.60% | 3.76 | 3.95 | 3.66 |
| Apr 2, 2025 | 3.88 | -0.18 | -4.43% | 4.06 | 4.39 | 3.75 |
| Apr 1, 2025 | 4.11 | -0.40 | -8.87% | 4.51 | 4.51 | 4.08 |
| Mar 31, 2025 | 4.52 | -0.47 | -9.42% | 4.99 | 4.99 | 4.52 |
| Mar 28, 2025 | 5.19 | -0.01 | -0.19% | 5.20 | 5.34 | 5.12 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Verve Therapeutics, Inc. Company profile
About Verve Therapeutics Inc
Verve Therapeutics, Inc. is a genetic medicines company. The Company is engaged in pioneering a new approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. It is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes to lower blood lipids. The Company's initial two programs focuses on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. Its pipeline of in vivo gene editing programs for atherosclerotic cardiovascular disease (ASCVD) includes VERVE-101 and ANGPTL3. The Company's lead product candidate, VERVE-101, is designed to be a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Verve Therapeutics Inc revenues was not reported. Net loss increased from $45.7M to $120.3M. Higher net loss reflects Fair Value of antidilution rights increase from $5.4M to $25.6M (expense), Fair Value Adjustment of success payment increase from $2.4M to $7.8M (expense), Interest Income - Non Bank decrease of 12% to $142K (income).
| Industry: | Biotechnology & Medical Research (NEC) |
201 Brookline Avenue
Suite 601
BOSTON
MASSACHUSETTS 02215
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com